🇺🇸 FDA
Patent

US 9457070

Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease

granted A61KA61K2035/124A61K31/60

Quick answer

US patent 9457070 (Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2035/124, A61K31/60, A61K35/28, A61K38/12